Coco Kou
Director of Finance/CFO bij QHY GROUP
Profiel
Coco Kou is currently the Chief Financial Officer at QHY Group and the Chief Financial & Accounting Officer at Four Leaf Acquisition Corp.
Prior to these roles, Ms. Kou served as the Chief Financial Officer at Xynomic Pharmaceuticals Holdings, Inc. from 2019 to 2021.
Ms. Kou holds an undergraduate degree and a graduate degree from Peking University, an MBA from the University of Hong Kong, London Business School, and Columbia Business School.
Actieve functies van Coco Kou
| Bedrijven | Functie | Begin |
|---|---|---|
| QHY GROUP | Director of Finance/CFO | - |
| FOUR LEAF ACQUISITION CORPORATION | Director of Finance/CFO | 01-01-2022 |
Eerdere bekende functies van Coco Kou
| Bedrijven | Functie | Einde |
|---|---|---|
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Director of Finance/CFO | 01-01-2021 |
Opleiding van Coco Kou
| Peking University | Graduate Degree |
| University of Hong Kong | Masters Business Admin |
| London Business School | Masters Business Admin |
| Columbia Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| QHY GROUP | Industrial Services |
| FOUR LEAF ACQUISITION CORPORATION | Finance |
| Bedrijven in privébezit | 1 |
|---|---|
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
